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Glucagon plays an important role in glucose homeo-
stasis by regulating hepatic glucose output in both
normo- and hypoglycemic conditions. In this study,
we created and characterized a cell-specific insulin
receptor knockout (aIRKO) mice to directly explore
the role of insulin signaling in the regulation of
glucagon secretion in vivo. Adult male aIRKO mice
exhibited mild glucose intolerance, hyperglycemia,
andhyperglucagonemia in the fedstate andenhanced
glucagon secretion in response to L-arginine stimula-
tion. Hyperinsulinemic-hypoglycemic clamp studies
revealed an enhanced glucagon secretory response
andanabnormalnorepinephrine response tohypogly-
cemia in aIRKO mice. The mutants also exhibited an
age-dependent increase in b cell mass. Furthermore,
siRNA-mediated knockdown of insulin receptor in
glucagon-secreting InR1G cells promoted enhanced
glucagon secretion and complemented our in vivo
findings. Together, these data indicate a significant
role for intraislet insulin signaling in the regulation of
a cell function in both normo- and hypoglycemic
conditions.
INTRODUCTION
Type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus
(T2DM) are both characterized by uncontrolled hyperglycemia,
and maintenance of blood glucose within the physiological range
is critical for the prevention of diabetes-related complications.
However, tight glycemic control is also associated with an
increased incidence of therapy-induced hypoglycemic events
(Cryer, 1994; DCCT, 1997).
Glucagon, secreted from the pancreatic a cells, counters the
actions of insulin and corrects hypoglycemia by enhancing
hepatic glucose output and gluconeogenesis (Exton et al.,
1966; Unger and Orci, 1977). Inappropriate glucagon secretion
is often observed in patients with diabetes, and a defective
glucagon response to hypoglycemia in hyperinsulinemic states
frequently exacerbates hypoglycemic attacks and limits intensive350 Cell Metabolism 9, 350–361, April 8, 2009 ª2009 Elsevier Inc.insulin therapy (Amiel et al., 1988; Gerich et al., 1973). On the other
hand, excess glucagon secretion (Unger, 1978) and increase in
a cells in pancreatic islets in type 1 (Orci et al., 1976) and type 2
diabetes (Yoon et al., 2003) have been reported to worsen the
hyperglycemia. In addition to its effects on insulin secretion
(Scheen et al., 1996), glucagon has also been suggested to play
a role in the development of b cells, although the molecular
mechanisms underlying these effects are not fully understood
(Prasadan et al., 2002; Vuguin et al., 2006). Thus, investigating
the mechanism(s) that regulate a cell secretory function and
growth is useful to plan therapeutic approaches for preventing
hypoglycemia and improving glucose homeostasis in diabetes.
The secretion of glucagon from a cells is elevated in states of
hypoglycemia and suppressed by hyperglycemia (Gromada
et al., 2007). Whereas some studies suggest a direct effect of
glucose on a cell secretory function (Ravier and Rutter, 2005;
Vieira et al., 2007), additional regulators include the central
and/or autonomic nervous systems (Ahren, 2000; Bloom et al.,
1978; Evans et al., 2004; Marty et al., 2005) and intraislet para-
crine factors, including insulin (Diao et al., 2005; Gerich et al.,
1975; Greenbaum et al., 1991; Maruyama et al., 1984; Ravier
and Rutter, 2005; Stagner and Samols, 1986), somatostatin (Ger-
ich et al., 1974), g-aminobutyric acid (GABA) (Rorsman et al.,
1989), and Zinc ions (Zn) (Ishihara et al., 2003). Zn, coreleased
with insulin, has been reported to suppress glucagon release
(Ishihara et al., 2003) and, conversely, to stimulatea cell secretion
when its concentration falls as part of a ‘‘switch-off’’ mechanism
(Zhou et al., 2007). Intraislet insulin has been reported to act either
by reducing the sensitivity of K+-ATP channels (Franklin et al.,
2005) through phosphatidylinositol 3-kinase (PI3K) (Leung
et al., 2006) or by activating Akt, a critical downstream effector
of PI3K, which, in turn, induces recruitment of the GABA-A
receptor to the cellular membrane to allow its ligand, GABA, to
inhibit glucagon secretion (Xu et al., 2006). It is likely that one or
more of these factors act in concert to regulate a cell function
during different physiological states. However, there are no
reports, to our knowledge, that provide direct in vivo evidence
for a direct role for intraislet insulin in the modulation ofacell func-
tion, especially when insulin sensitivity is normal in peripheral
tissues. Here, we report the creation of a a cell-specific insulin
receptor knockout mouse and provide genetic evidence that
insulin signaling is important for the regulation of glucagon secre-
tion in both normoglycemic and hypoglycemic states in vivo.
Cell Metabolism
Insulin Signaling and Pancreatic a CellsFigure 1. a Cell-Specific Recombination, Fed Hyperglycemia, and Hyperglucagonemia in aIRKO Mice
(A) Two individual islets from pancreas sections of glucagon-Cre/ROSA26-LacZ mice are shown. Scale bar,100 mm. Magnification, 340.
(B) Recombination of insulin receptor in hypothalamus assessed by RT-PCR. Positive control, bIRKO b cells; negative control, LoxLox b cells.
(C) Food intake in 2- and 6-month-old male mice. n = 6 in each group.
(D) Body weights in 6-month-old male and female mice. n = 8–12 in each group.
(E–G) (E) Blood glucose, (F) plasma insulin, and (G) plasma glucagon were measured after an overnight (16 hr) fast or in random-fed states in 2-, 5-, and 12-month-
old males. n = 6–8 in each group.
(H) Insulin/glucagon ratio.
Control, empty bar; aIRKO, filled bar. Data are expressed as means ± SEM; *p < 0.05; control versus aIRKO.RESULTS
Creation of a Cell-Specific Insulin Receptor
Knockout Mice
a cell-specific insulin receptor (IR) knockout (aIRKO) mice were
created by crossing mice carrying the insulin receptor-floxed
gene (Kulkarni et al., 1999a) with mice expressing Cre recombi-
nase driven by the glucagon promoter (Herrera, 2000). aIRKO
mice were born in a normal Mendelian pattern and did not exhibit
abnormalities in the postnatal period. The specificityof recombina-
tion by the glucagon-promoter-driven Cre recombinase (Glu-Cre)
was confirmed by crossing ROSA26-LacZ reporter mice (Soriano,
1999) with Glu-Cre mice and immunostaining for b-galactosidase
(b-gal) in pancreatic islets, hypothalamus, and intestinal L cells
(Gromada et al., 2007; Kieffer and Habener, 1999). Nearly 85%
of the a cells expressed b-gal, indicating a high rate of recombina-
tion and high specificity because the other islet cell types ex-
pressed significantly low levels of b-gal (Figure 1A; insulin+ cells
[0.01 ± 0.01% in 5000 cells], glucagon+ cells [83 ± 4.4% in 2000
cells], somatostatin+ cells [0.01 ± 0.01% in 200 cells]; n = 4 mice).No significant expression ofb-gal was detected in the hypothal-
amus or in other regions of the brain (data not shown). Further,
RT-PCR of RNA extracted from hypothalamus revealed no
recombination product in the hypothalamus of aIRKO mice
(Figure 1B). Consistent with these data, food intake (Figure 1C)
and body weights (Figure 1D) were not significantly different
between groups. Interestingly, we observed b-gal in a small
number of cells (<5%) in the small intestine, indicating some
recombination in L cells that are known to secrete glucagon-like
peptide-1 (GLP-1) (data not shown). However, the plasma GLP-1
levels were unaltered between genotypes (8-month-old, random
fed; male: control 4.00 ± 1.64 pM, aIRKO 3.61 ± 0.43 pM; female:
control 3.94 ± 0.87 pM, aIRKO 4.15 ± 0.65 pM; means ± SEM; p =
NS; n = 3–5 in each group), suggesting that the small amount of
recombination did not impact secretion of GLP-1.
aIRKO Mice Exhibit Hyperglycemia,
Hyperglucagonemia, and Glucose Intolerance
aIRKO mice exhibited up to 50% higher blood glucose levels
compared to controls in the fed state, whereas no significantCell Metabolism 9, 350–361, April 8, 2009 ª2009 Elsevier Inc. 351
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Insulin Signaling and Pancreatic a CellsFigure 2. Mild Glucose Intolerance and Enhanced Glucagon Secretion in aIRKO Mice
(A) Glucose tolerance in 2- and 5-month-old male mice. n = 3–12 in each group.
(B) Whole-body insulin sensitivity (at insulin doses 0.5 and 1 U/kg bw) in 2- and 5-month-old male mice. n = 3–5 in each group.
(C) Insulin and glucagon responses to L-arginine were assessed by intraperitoneal L-arginine stimulation test in 2- and 5- to 6-month-old male mice. n = 4–6 in
each group.
(D) Plasma glucagon was assessed in the random fed state before and after streptozotocin treatment.n = 6–7 ineach groupbefore treatment; n = 3–4after treatment.
(E–H) (E and F) Insulin and (G and H) glucagon secretion were examined by ex vivo whole-pancreas perfusion.
Control, empty square; aIRKO, filled triangle. Data are expressed as means ± SEM; *p < 0.05; control versus aIRKO.differences were observed in fasting blood glucose levels
between groups (Figure 1E). The 2-month-old male aIRKO mice
also showed higher levels of plasma glucagon compared to
controls in both fasted and fed states, and the hyperglucagone-
mia persisted only in the fed state at older ages (Figure 1G).
Though no significant differences in plasma insulin levels were
detected between groups in the fasting state, aIRKO mice
exhibited elevated plasma insulin levels at 5 and 12 months of
age in the fed state (Figure 1F). Further, the insulin:glucagon ratio
was relatively stable in the controls in both fasted and fed states
compared to an altered ratio in the fed state in the aIRKOs
(Figure 1H). Intraperitoneal (IP) glucose tolerance tests (IPGTT) re-
vealed glucose intolerance in aIRKO mice at 2 and 5 months of
age (Figure 2A). The mutants exhibited normal whole-body insulin
sensitivity, as assessed by intraperitoneal insulin tolerance tests
(IPITT) at 1 U/kg body weight (bw) insulin. However, we observed352 Cell Metabolism 9, 350–361, April 8, 2009 ª2009 Elsevier Inc.a tendency to insulin resistance at a lower dose of insulin (0.5 U/kg
bw; p = 0.07 at 60 min) (Figure 2B), suggesting an unmasking of
glucagon-induced hepatic insulin resistance. Further, 30 min after
the insulin injection in 2-month-old mice (1 U/kg bw), plasma
glucagon was significantly higher in the knockouts (control
219.9 ± 40.2 pg/ml, aIRKO 359.0 ± 41.7 pg/ml; n = 3–5 in each
group; p < 0.05), whereas blood glucose and plasma insulin levels
were comparable between groups (data not shown). Together,
these data indicate abnormalities in the regulation of glucagon
secretion leading to altered glucose homeostasis.
Enhanced L-Arginine-Stimulated Glucagon Secretion
in aIRKO Mice
Because L-arginine stimulates both a and b cells (Unger et al.,
1970), we examined hormone secretion in vivo in response to
L-arginine stimulation in 2-month-old and 5- to 6-month-old
Cell Metabolism
Insulin Signaling and Pancreatic a Cellsmice.Asexpected, L-arginine significantlystimulated insulinsecre-
tion in both groups, and no significant differences were observed
(Figure 2C, left panels). Consistent with loss of insulin signaling in
a cells, we observed significantly higher glucagon secretion in
aIRKO mice compared to controls (Figure 2C, right panels).
To assess the effects of L-arginine, independently of systemic
insulin sensitivity and neural influence, we performed ex vivo
whole-pancreas perfusion experiments. In situ pancreas perfu-
sions were performed in aIRKO mice in which the glucose
concentration in the perfusate was increased progressively
from 2 to 20 mM over 100 min. At this point, 20 mM L-arginine
was added to the perfusion in the continued presence of 20 mM
glucose for an additional 26 min. We observed no significant
difference between groups in glucose-stimulated insulin secre-
tion (Figures 2E and 2F). However, the increment in glucagon
secretion after L-arginine infusion (Figure 2G, area under curve
from 110 to 126 min) was significantly higher in the mutant mice
(Figure 2H), indicating enhanced L-arginine-stimulated glucagon
secretion. These data are consistent with the in vivo findings
(Figure 2C) and are likely due to an absence of intraislet insulin-
mediated inhibition of glucagon secretion in aIRKO mice. The
glucose concentration used in the perfusion model is relatively
high (20 mM); in future studies, it will be useful to test the insulin
dependency of glucagon suppression in the aIRKOs by using
a glucose concentration in the physiological range.
Glucagon Secretion in STZ-Treated Mice
Next, we treated both controls and mutants with streptozotocin
(STZ) and induced insulin-deficient diabetes characterized by in-
sulinopenia and hyperglycemia (Figure S1 available online).
Plasma glucagon was elevated and reached similar levels in
both groups (Figure 2D), supporting the concept that either the
insulinopenia or hyperglycemia, or a combination of both,
enhances glucagon secretion. These data suggest that, in the
controls, imposition of insulinopenia and hyperglycemia leads
to a glucagon secretion response (Figure 2D). In the aIRKOs,
which are already blind to ambient insulin, the lack of a further
increase in plasma glucagon levels that is even higher than
controls in response to the hyperglycemia suggests a dominant
role for insulin in the suppression of glucagon secretion (Meier
et al., 2006). Future studies aimed at long-term therapy of STZ-
treated aIRKO mice, with exogenous insulin, to normalize glyce-
mia followed by assessment of glucagon secretory responses to
induction of hypoglycemia will be useful to simulate the scenario
observed in human patients with long-standing type 1 diabetes
that are undergoing chronic treatment with insulin.
Enhanced Glucagon Secretion in Hyperinsulinemic-
Hypoglycemic Clamp Studies in aIRKO Mice
Glucagon plays important roles both in euglycemic and hypogly-
cemic conditions. To assess the role of insulin signaling in a cells
in vivo during hypoglycemia, we performed hyperinsulinemic-
hypoglycemic clamp experiments in 2-month-old aIRKO and
control mice (Figure 3A). Hypoglycemia-stimulated glucagon
secretion was significantly higher in aIRKO mice 30 min after initia-
tion of the insulin infusion (Figure 3C) and may have contributed to
the lower glucose infusion rate (GIR) observed in the mutants
(Figure3B).Furthermore,aIRKOmiceexhibitedhighernorepineph-
rine levels at baseline and in response to hypoglycemia (Figure 3D),whereas epinephrine and corticosterone responses to hypogly-
cemia were not significantly different between groups (Figures 3E
and 3F). The higher glucagon secretion in aIRKO mice suggests
that the hyperinsulinemia was unable to suppress glucagon secre-
tion in the mutants to the same extent as the controls due to the
absence of insulin receptors in the former, and it supports a direct
role for insulin receptors in modulating a cell secretory function.
Blunted Glucagon Response to Fasting-Induced
Hypoglycemia in aIRKO Mice
To assess the effect of insulin receptor disruption on a cell func-
tion in response to physiological hypoglycemia, we subjected
6-month-old control and aIRKO mice to fasting and refeeding.
Although both groups showed the expected decrease in body
weights (Figure 4B) and blood glucose (Figure 4A), the aIRKOs
exhibited mild hyperglycemia during the fasting period. The
control mice exhibited a tendency of increasing plasma glucagon
in response to physiological hypoglycemia induced by fasting
and decreasing glucagon in the refed state (Figure 4C), consistent
with a decrease in plasma insulin levels during fasting and an
increase following refeeding (Figure 4D). However, the glucagon
secretory response to fasting-induced hypoglycemia was not
only blunted but was even lower than in the fed state in the aIRKO
mice (Figure 4C) and was followed by a trend to an increase
during refeeding, suggesting abnormal secretory responses
when insulin signaling is absent in the a cells (Figure 4C).
To examine the effect of glucopenia in the absence of hypergly-
cemia, we treated 6-month-old mice with phloridzin for 14 days.
Both groups exhibited a significant decrease in random fed blood
glucose levels without a significant alteration in plasma insulin
levels (Figure S2). The glucagon response was unaltered between
treated and nontreated groups in both groups (Figure S2), sug-
gesting that, in the aIRKOs, reducing blood glucose levels does
not modulate a cell function further.
Attenuated Suppression of Hepatic Gene Expression
following Fasting and Refeeding in aIRKO Mice
Because the liver is a major target for glucagon action, we
explored alterations in hepatic gene expression patterns in hyper-
glucagonemic aIRKO mice in fed and fasting conditions, with
a focus on hepatic glucose metabolism. Except for a higher gluco-
kinase (Gck) expression in the aIRKOs, no other significant differ-
ences were observed between groups in the expression of genes
involved in hepatic glucose metabolism in the fasting state
(Figures 4E–4H). Following refeeding, both groups showed the
expected patterns of a decrease in phosphoenolpyruvate carbox-
ykinase (PEPCK, Pepck) and glucose 6-phosphatase (G6Pase,
G6pc) (Figures 4E and 4F). However, the decrease in G6pc was
significantly attenuated, whereas suppression of Pepck was
marginal in the aIRKO mice compared to controls (Figures 4E
and 4F), suggesting one possible explanation for the mild hyper-
glycemia in aIRKO mice. A significant increase in Gck and fatty
acid synthase (Fasn) following refeeding (Figures 4G and 4H) indi-
cated a largely intact hepatic response in the mutant animals.
Alterations in Glucagon and Insulin Gene Expression
in Isolated Islets from aIRKO Mice
Our in vivo results clearly suggest a role for insulin signaling in the
regulation of glucagon secretion. To examine the potential effectsCell Metabolism 9, 350–361, April 8, 2009 ª2009 Elsevier Inc. 353
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Insulin Signaling and Pancreatic a CellsFigure 3. Hyperinsulinemic-Hypoglycemic Clamp and Counterregulatory Responses in aIRKO Mice
The mice were continuously infused with insulin and glucose to maintain hypoglycemia.
(A and B) (A) Blood glucose and (B) glucose infusion rate were measured every 10 min.
(C–F) At 0, 30, and 120 min of the clamp experiment, (C) glucagon, (D) norepinephrine, (E) epinephrine, and (F) corticosterone response were examined. n = 4–5 in
each group.
Control, empty circle; aIRKO, filled triangle. Data are expressed as means ± SEM; *p < 0.05; control versus aIRKO.at the transcriptional level, we studied insulin (Ins 1) and glucagon
(Gcg) gene expression in response to glucose stimulation (3 or
11 mM) of islets isolated from aIRKOs and controls. High glucose
stimulated glucagon gene expression significantly inaIRKO islets,
but not in controls (Figure 5A), suggesting that glucose-stimulated
increase in glucagon gene expression is higher due to the lack of
a tonic suppressive effect of intraislet insulin in a cells (Philippe,
1989). Furthermore, this increase in glucagon gene expression
persisted even in the presence of 100 nM insulin only in aIRKO
islets (Figure 5A). On the other hand, glucagon gene expression
in response to low glucose stimulation was significantly reduced
in aIRKO islets, whereas it caused a nonsignificant change in
the control group (Figure 5B). Taken together, these data indicate
that insulin signaling in the a cells regulates glucagon gene
expression in both high- and low-glucose conditions.354 Cell Metabolism 9, 350–361, April 8, 2009 ª2009 Elsevier Inc.High glucose stimulated and low glucose inhibited insulin gene
expression to comparable levels in control and aIRKO islets
(Figures 5C and 5D). Interestingly, aIRKO islets exhibited a
significantly higher insulin gene expression in response to high
glucose stimulation, and the addition of 100 nM insulin to
the high glucose stimulation media further enhanced insulin
gene expression in the aIRKO islets, but not in the controls, sug-
gesting that b cells in aIRKO islets are more sensitive to insulin
(Figure 5C).
Progressive Increase in b Cell Mass and Relative
Decrease in a Cell Mass in aIRKO Mice
To determine whether insulin signaling in a cells plays a role in
a cell growth and proliferation, we assessed pancreatic islet
morphology in 6- and 12-month-old animals (Figure 6A).
Cell Metabolism
Insulin Signaling and Pancreatic a CellsFigure 4. Glycemic Parameters and Hepatic Gene Expression in aIRKO Mice
The mice were subjected to 36 hr fasting followed with 12 hr refeeding.
(A and B) (A) Blood glucose and (B) body weight were measured every 12 hr. n = 4–8 in each group.
(C and D) (C) Plasma glucagon and (D) insulin were measured in the fed, 36 hr fast, and 12 hr refed conditions. n = 4–8 in each group.
Control, empty square; aIRKO, filled triangle. Data are expressed as means ± SEM; *p < 0.05; control versus aIRKO.
(E–H) Hepatic expression of (E) PEPCK, (F) G6Pase, (G) glucokinase, and (H) fatty acid synthase genes were quantified by real-time PCR and normalized to TBP.
n = 4 in each group. Control, empty bar; aIRKO, filled bar. Data are expressed as means ± SEM; *p < 0.05, **p < 0.01; between indicated groups.Although aIRKO mice exhibited a relatively normal islet archi-
tecture with a cells distributed in the periphery, we observed
an age-dependent hyperplasia compared to controls (Fig-
ure 6A). Further, the trend to an age-dependent increase in
a cell area in the control islets was absent in the aIRKOs (Fig-
ure 6B). Interestingly, the b cell area in 12-month-old aIRKO
mice was significantly increased compared to controls
(Figure 6B), suggesting that altered insulin signaling in a cells
has indirect effects on b cell proliferation. The number and
distribution of d cells were unaltered, and ghrelin-positive cells
were not detectable in the islets from either control or aIRKO
mice (Figure 6C). The presence of ghrelin-positive cells in
neonatal pancreas confirmed a working anti-ghrelin antibody
(Figure S3). Immunostaining for PDX-1 and MafB, two transcrip-
tion factors shown to be important in b and a cell development,
also revealed no significant difference between groups in
12-month-old mice (Figure 6D). Gene array analyses of islets
from 3- and 10-month-old mice with PancChip (Scearce et al.,
2002) also revealed no significant differences in the expression
of transcription factors known to be important for islet cell
development except for a mild increase in Pax4 in old aIRKO
mice (Table S1).Knockdown of Insulin Receptors in InR1G Cells
Promotes Enhanced Glucagon Secretion
Glucagon-secreting InR1G cells were transfected with prede-
signed siRNA for insulin receptor or scrambled control RNA,
leading to 85% knockdown of insulin receptor protein in the
siRNA-treated groups (Figure 7A). Both p-Akt/PKB and p-FoxO1
were significantly reduced in InR1G cells treated with siRNA for
insulin receptor, consistent with the knockdown (Figure 7A).
At both low (3.3 mM) and high (25 mM) glucose concentrations,
InR1G cells with a knockdown of insulin receptor secreted more
glucagon compared to control scramble siRNA-transfected cells
(Figure 7B). Next, we examined glucagon secretion in response
to L-arginine (10 mM), a known stimulator of glucagon secretion
by a cells (Unger et al., 1970). Again, siRNA for insulin receptor-
treated InR1G cells secreted significantly more glucagon
compared to controls (Figure 7B), whereas the glucagon content
showed a trend to an increase but did not reach statistical signif-
icance compared to controls (Figure 7C). These findings support
a role for insulin signaling in glucagon secretion in response to
glucose and L-arginine, but not glucagon biosynthesis in InR1G
cells, consistent with a direct role for insulin signaling in the regu-
lation of glucagon secretion by a cells.Cell Metabolism 9, 350–361, April 8, 2009 ª2009 Elsevier Inc. 355
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Insulin Signaling and Pancreatic a CellsFigure 5. Impact of a Cell-Specific Insulin Receptor Disruption on Insulin and Glucagon Gene Expression
(A and C) Effect of incubating islets from low (3 mM) to high (11.1 mM) glucose or (B and D) high (11.1 mM) to low (3 mM) glucose on glucagon (A and B) or insulin
gene expression (C and D). Fold changes were calculated relative to controls. n = 3 each in each group. Control, empty bar; aIRKO, filled bar. Data are expressed
as means ± SEM; *p < 0.05; versus 3 mM to 3 mM control group (C), versus 11 mM to 11 mM control group (D). #p < 0.05; versus 3 mM to 3 mM aIRKO group (A
and C), versus 11 mM to 11 mM aIRKO group (B and D).DISCUSSION
To directly examine whether insulin signaling modulates
glucagon secretion in vivo, we created and characterized mice
with a conditional knockout of the insulin receptor in pancreatic
a cells (aIRKO mice). Adult male aIRKO mice exhibited hyperglu-
cagonemia, glucose intolerance, hyperglycemia in fed states,
and an elevated glucagon response to L-arginine stimulation.
Hyperinsulinemic-hypoglycemic clamp studies revealed an
enhanced glucagon secretory response in aIRKO mice. These
in vivo findings were complemented by enhanced glucagon
secretion in siRNA-mediated knockdown of the insulin receptor
in InR1G cells. Together, these data provide direct genetic
evidence for a significant role for the insulin receptor in the
modulation of pancreatic a cell function.
The regulation of glucagon secretion involves a complex inter-
play of signals, including glucose, intraislet paracrine factors, and
the central and autonomic nervous systems (Gromada et al.,
2007). Insulin, secreted from b cells, has been proposed as one
of the intraislet paracrine factors that can modulate the secretion
of glucagon by neighboring a cells (Asplin et al., 1981; Maruyama
et al., 1984; Weir et al., 1976). Although several ex vivo (e.g., iso-
lated islets) and/or in vitro (e.g., dispersed islet cells) approaches
(reviewed in Cryer, 1994; Gromada et al., 2007) have been used to
address the role of intraislet insulin, these studies do not mimic
the in vivo situation in which the direction of blood flow frombcells356 Cell Metabolism 9, 350–361, April 8, 2009 ª2009 Elsevier Inc.can potentially influence the function of a cells located down-
stream (Bonner-Weir and Orci, 1982; Samols and Stagner,
1988). The aIRKO mouse model circumvents these limitations
and provides direct in vivo evidence that disrupting insulin
signaling inacells leads to hyperglucagonemia and glucose intol-
erance. The relatively mild hyperglucagonemia in the aIRKOs did
not translate to major defects in hepatic gene expression patterns
in the nonstressed mouse. However, subjecting the aIRKOs to
fasting stress led to a significant attenuation of the decrease in
expression of hepatic glucokinase, whereas after refeeding, the
decrease in hepatic G6Pase expression was also significantly
lower compared to the response in controls. It is possible that
a lack of appropriate suppression of glucokinase and G6Pase,
which are both important for hepatic glucose metabolism (Barthel
and Schmoll, 2003), contributed, in part, to the glycemic pertur-
bations in the aIRKOs.
Intraislet insulin has been implicated in the glucagon counter-
regulatory response that is necessary to prevent hypoglycemia
(Ahren, 2000; Gromada et al., 2007). To directly assess the role
of intraislet insulin in the aIRKO model, we used two paradigms
of hypoglycemia. Subjecting the mice to hyperinsulinemic hypo-
glycemia revealed significantly reduced glucagon release in
controls compared to aIRKOs, suggesting that the concomitant
elevation in insulin suppresses the a cell secretory response to
hypoglycemia in the controls, but not in aIRKOs. The lack of
suppression in the aIRKOs is likely due to absent insulin signaling
Cell Metabolism
Insulin Signaling and Pancreatic a CellsFigure 6. Pancreas Morphometry in aIRKO Mice
Pancreas sections were immunostained as indicated (A, C, and D; scale bar, 50 mm; magnification,340). (B) b and a cell mass were quantified at 6 and 12 month
old. n = 4–5 in each group. Somatostatin, ghrelin, PDX-1, and MafB were immunostained in 12-month-old controls and mutants. Control, empty bar; aIRKO, filled
bar. Data are expressed as means ± SEM; *p < 0.05; control versus aIRKO.in a cells that, in turn, allows a greater glucagon secretory
response to hypoglycemia despite lower sympathetic (i.e.,
norepinephrine) tone. The similar rise in epinephrine levels in
the two groups indicates that the effects of the experimental
hypoglycemia on a cell secretion are independent of circulating
epinephrine (Gromada et al., 2007). It is also possible that the
additional deficiency in epinephrine-induced counterregulatory
defense against hypoglycemia, which is observed in many
patients with type 1 diabetes (Heller and Cryer, 1991; Mokan
et al., 1994; Powell et al., 1993), is due to chronic hypoglycemia
and is not fully manifest in the aIRKO mice. The lower norepi-
nephrine (basal and hypoglycemic) response in the aIRKOs
suggests that insulin signaling in a cells potentially signals to
the brain to recruit the sympathetic nervous system to partici-
pate in the hypoglycemic response (Gromada et al., 2007).
However, it is worth noting that changes in systemic levels of
norepinephrine have been reported to be the result of ‘‘spill-
over’’ and are considered nondiscriminatory in clamp studies
(Evans et al., 2004; McCrimmon et al., 2005). The aIRKO mouse
provides a useful model to evaluate whether additional neuronal
signals can contribute to counterregulatory glucagon responses
in the absence of the effects of intraislet insulin. Glucose infusion
rates (GIR) are typically expected to be low during hypoglycemic
clamps when compared to euglycemic clamps (Jacobson et al.,
2006), due to the combined effects of the decrease in the massaction of glucose (suppress the liver glucose production and
augment muscle glucose uptake) and of the increased counter-
regulatory hormones opposing insulin action. The lower GIR in
the aIRKO mice during the hypoglycemic clamp may be due,
in part, to hepatic insulin resistance induced by higher glucagon
responses. It is conceivable that insulin sensitivity is lower as
well, and studies with euglycemic clamps may shed further light
on this phenomenon.
In a second paradigm, when hypoglycemia was induced by
fasting but without a substantial decrease in insulin levels, the
circulating glucagon levels did not drop in controls. These data
suggest that a switch-off mechanism (Hope et al., 2004; Zhou
et al., 2004) may not operate in vivo, and the recognition of
a significant decrease in circulating insulin by insulin receptors
in a cells is necessary for an appropriate glucagon secretory
response to hypoglycemia. The aIRKO mouse would be a useful
tool to further distinguish the significance of glucose versus
somatostatin in the intraislet control of a cell secretion (Green-
baum et al., 1991).
The alterations in glucagon gene expression in the aIRKO
islets exposed to different concentrations of glucose indicate
a regulatory role for insulin signaling in a cells at the level of tran-
scription, consistent with previous studies (Gonzalez et al., 2008;
Philippe, 1989). Because glucose is an important physiological
suppressor of glucagon secretion in vivo (Gromada et al.,Cell Metabolism 9, 350–361, April 8, 2009 ª2009 Elsevier Inc. 357
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glucose (Salehi et al., 2006) has led to the suggestion that addi-
tional modulator(s) exist for glucagon suppression in vivo. Our
observations of enhanced glucagon secretion in InR1G cells
with a knockdown of insulin receptors complement our in vivo
findings and indicate that the additional modulator is insulin itself
or that the putative modulator requires a functional insulin
receptor for its effects on a cells. Although InR1G cells do not
secrete insulin (Drucker et al., 1988), it is possible that the insulin
present in growth media used to routinely culture and maintain
the cells has a suppressive effect on glucagon secretion that is
unmasked in the controls, but not in the knockdown cells.
Further support for a direct role for insulin in the regulation of
a cell function is provided by the observation that glucagon
secretion is abolished in response to low glucose in isolated
islets and in aTC6 cells expressing insulin receptor siRNA
(Diao et al., 2005).
Surprisingly, we observed an increase in b cell mass and
a decrease in a cell mass in the aIRKO mice. Given the potential
Figure 7. Enhanced Glucagon Secretion in InR1G Cells with Insulin
Receptor Knockdown
(A) Western blots for insulin receptor, phospho- and total Akt, phospho- and
total FoxO1, and actin for loading control. Representative of three independent
experiments.
(B) Glucagon secretion was assessed by static incubation for 60 min and ex-
pressed per mg of total protein. n = 6 in each group.
(C) Total protein content and total glucagon content. n = 3 in each group.
Scrambled siRNA, empty bar; siRNA for insulin receptor, filled bar. Data are
expressed as means ± SEM; *p < 0.05, **p < 0.01; scramble versus siRNA
for insulin receptor.358 Cell Metabolism 9, 350–361, April 8, 2009 ª2009 Elsevier Inc.role for glucagon in the development of b cells (Prasadan et al.,
2002; Vuguin et al., 2006), it is conceivable that alteredacell func-
tion in theaIRKO mice directly or indirectly influences b cell prolif-
eration in the mutants. On the other hand, the reduced a cells in
older aIRKO mice may be secondary to attenuation of insulin
signaling-mediated antiapoptosis leading to increased a cell
death, an observation that is similar to the reduced b cell mass
in b cell-specific insulin receptor knockout mice (Kulkarni et al.,
1999a). Alternatively, a-to-b cell transdifferentiation, which has
been suggested to involve the transcription factor aristaless-
related homeobox (Arx) (Collombat et al., 2003), may induce an
increase in b cells at the expense of a cells. PancChip analyses
of islets (Scearce et al., 2002) (Table S1) revealed no significant
differences between groups in the expression of transcription
factors, including PDX-1 and MafB, that are important for prolif-
eration and/or development of islets cells except for a marginal
increase in Pax-4 in theaIRKOs. Further investigation during early
development and postnatal periods is necessary to examine the
potential role of Pax4 in islet cell fate specification in the aIRKO
mice. Alternatively, lineage trace analyses could be useful to
explore whether the new b cells in the aIRKOs emerge from irre-
versibly marked a cells lacking growth factor signaling. Finally, it
will be worth exploring the individual contributions of insulin
versus IGF-I receptors and proteins in their signaling pathways
to the a cell hyperplasia that is observed in glucagon-resistant
models (Chen et al., 2005; Gelling et al., 2003).
In summary, we provide direct genetic evidence for a role for
insulin signaling in the regulation of a cell function in vivo. We
propose that insulin resistance in the a cell contributes to dysre-
gulation of glucagon secretion in altered glycemic states. These
data provide a basis for developing therapeutic approaches
aimed at modulating a cell growth and function with the long-
term goal of improving glucose homeostasis in patients with
T1DM and T2DM.
EXPERIMENTAL PROCEDURES
Animal and Physiological Experiments
Mice were housed in pathogen-free facilities and maintained on a 12 hr light/
dark cycle at the Animal Care Facility of Joslin Diabetes Center in Boston, MA
and the Foster Biomedical Research Laboratory of Brandeis University in Wal-
tham, MA. All protocols were approved by the Institutional Animal Care and Use
Committee of the Joslin Diabetes Center and Brandeis University and were in
accordance with NIH guidelines. Blood glucose was monitored with an auto-
mated glucose monitor (Glucometer Elite, Bayer), plasma insulin by ELISA
(Crystal Chem), plasma glucagon by RIA (Linco), and plasma GLP-1 by ELISA
(Linco). Fasting blood sampling and L-arginine stimulation tests were per-
formed 16 hr after fasting. Glucose and insulin tolerance tests were performed
as described previously (Kulkarni et al., 1999a). For L-arginine stimulation tests,
blood samples were collected before and after i.p. L-arginine injection (3 g/kg
bw) at 2 and 5 min for insulin and at 10 and 30 min for glucagon. Streptozotocin
(STZ; Sigma, 75 mg/kg bw) was injected in 3-month-old mice for 4 days.
Random fed blood samples were monitored 1 day before and 7 and 14 days
after the first STZ injection.
Insulin Secretion from the In Situ Perfused Pancreas
The pancreas was perfused in situ in a humidified temperature-controlled
chamber with a modification of a protocol described previously (Pontoglio
et al., 1998). After 100 min, 20 mM L-arginine was perfused in the continued
presence of 20 mM glucose for an additional 26 min. The increase in glucagon
secretion after L-arginine infusion was calculated as area under curve of the
absolute increase in glucagon between 110 and 126 min.
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of Counterregulatory Hormones
The hyperinsulinemic-hypoglycemic clamps were performed with a modifica-
tion of a protocol described previously (Jacobson et al., 2006). The mice were
subjected to clamps under conscious and unstressed conditions after 6 hr fast-
ing. Blood glucose level was maintained low with a target value of50 mg/dl for
120 min with insulin infusion at a rate of 10 mU/kg/min. At 0, 30, and 120 min,
blood was collected for measurement of counterregulatory hormones for hypo-
glycemia, including glucagon (RIA), epinephrine, norepinephrine (HPLC), and
corticosterone (RIA, Linco) (Jacobson et al., 2006).
Fasting Experiments
Mice were fasted for 36 hr, and blood glucose and body weights were
measured every 12 hr. Blood samples were obtained before and 36 hr after
fasting and 12 hr after refeeding. At 36 hr after fasting or 12 hr after refeeding,
the mice were sacrificed, and livers were harvested and stored at 80C for
extraction of RNA.
Assessment of Recombination and Gene Expression
Islets were obtained by collagenase digestion (Kulkarni et al., 1999a). Total
RNA from hypothalamus and isolated islets was extracted with RNeasy Mini
Kit (QIAGEN). RNA from b cell lines (Supplemental Experimental Procedures)
and liver was extracted by Trizol method (Invitrogen). cDNA samples were
generated by high-capacity cDNA Archive Kit (Applied Biosystems). Recombi-
nation of insulin receptor was detected as described previously (Kulkarni et al.,
1999a). In isolated islet studies, gene expression was assessed in healthy
hand-picked islets after 48 hr culture (Kulkarni et al., 1999a). Batches of
20 healthy size-matched islets were preincubated in RPMI-1640 media
containing 0.1% BSA and low (3 mM) or high (11.1 mM) glucose for 2 hr.
Subsequently, the islets were incubated in media containing 0.1% BSA, high
(preincubation, 3 mM glucose 2 hr; stimulation, 11.1 mM glucose 8 hr) or
low (preincubation, 11.1 mM glucose 2 hr; stimulation, 3 mM glucose 8 hr)
glucose with or without 100 nM insulin. Gene expression for insulin, glucagon,
and hepatic enzymes was determined by quantitative real-time PCR (Raey-
maekers, 2000) with appropriate primers (Supplemental Experimental Proce-
dures) and normalized for TBP (liver) or actin (islet).
Pancreas Morphometry
The mice were anesthetized, and pancreas was rapidly dissected, weighed,
and processed as described previously (Kulkarni et al., 1999a) and immuno-
stained for insulin (Linco), glucagon (Sigma), somatostatin (DAKO), ghrelin
(Phoenix Pharmaceuticals), PDX-1 (Chemicon), MafB (Bethyl Laboratories),
and b-galactosidase (MP Biomedicals) followed by amplification by TSA Fluo-
rescence systems (Perkin Elmer) (Morioka et al., 2007). a and b cell area were
analyzed as described previously (Kulkarni et al., 2002).
Cell Culture, Transfection of siRNA, and Glucagon
Secretion Analyses
Glucagon-secreting InR1G cells (a kind gift from Dr. J. Philippe) were cultured
as described (Philippe, 1989), and all experiments were performed in cells
between passages 6 and 9. At 48 hr before transfection, InR1G cells were
replated in 12-well plates/60 mm dishes and transfected with siRNA for insulin
receptor (SMARTpool; Dharmacon) or scramble controls (Silencer Negative
Control #1; Ambion) with LipofectAMINE 2000 reagent (Invitrogen). After
a further 48 hr, culture in RPMI-1640 media cells were harvested for hormone
secretion or protein expression studies. Cellular glucagon content was
assessed by acid ethanol extraction (Kulkarni et al., 1999b). The protein content
was measured by BCA protein assay (Pierce), and glucagon was measured by
RIA (Linco).
Western Blotting
For western blotting, 50 mg each of cellular protein extracts were used (Kawa-
mori et al., 2006). Antibodies used: rabbit anti-insulin receptor b chain and goat
anti-actin antibody (Santa Cruz Biotechnology) rabbit anti-Akt antibody, anti-
Ser473-phosphospecific Akt antibody, anti-FoxO1 antibody and anti-Ser256-
phosphospecific FoxO1 antibody (Cell Signaling Technology), anti-rabbit IgG
horseradish peroxidase (HRP)-conjugated secondary antibody (Santa Cruz
Biotechnology), and anti-goat IgG HRP-conjugated secondary antibody(Zymed Laboratories). Relative protein amounts were estimated by densitom-
etry (Fluorchem IS-8000 image analyzer; Alpha Innotech).
Statistics
All data are presented as mean ± SEM and analyzed with an unpaired two-
tailed Student’s t test or analysis of variance (ANOVA) and post hoc tests as
appropriate. A p value less than 0.05 was considered significant.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, three
figures, and one table and can be found online at http://www.cell.com/
cell-metabolism/supplemental/S1550-4131(09)00066-7.
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